188
Participants
Start Date
May 23, 2019
Primary Completion Date
August 7, 2025
Study Completion Date
August 7, 2025
Mosunetuzumab Intravenous (IV)
Participants in cohorts A and B will receive IV mosunetuzumab.
Mosunetuzumab Subcutaneous (SC)
Participants in Cohort C will receive SC mosunetuzumab.
Polatuzumab Vedotin
Participants in Cohort C will receive IV polatuzumab vedotin.
Tocilizumab
Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
National Taiwan University Hospital, Taipei
Hospital San Pedro de Alcantara, Cáceres
Fox Chase Cancer Center, Philadelphia
University of Maryland Medical Center, Baltimore
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario 12 de Octubre, Madrid
Rambam Medical Center, Haifa
Hospital Universitario Virgen Macarena, Seville
Keimyung University Dongsan Hospital, Daegu
Fort Wayne Medical Institute, Fort Wayne
Pusan National University Hospital, Busan
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Hadassah Ein-Karem, Jerusalem
Carmel medical center, Haifa
Meir Medical Center, Kfar Saba
Sheba Medical Center, Ramat Gan
Soroka Medical Center, Beersheba
Shaare Zedek Medical Center, Jerusalem
University of Alabama at Birmingham School of Medicine, Birmingham
University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica, Santa Monica
Duke University, Durham
Rhode Island Hospital, Providence
Uniwersyteckie Centrum Kliniczne, Gdansk
PRATIA MCM Kraków, Krakow
Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli, Lublin
Szpital Wojewodzki w Opolu, Opole
Samsung Medical Center, Seoul
The Catholic University of Korea Yeouido St. Mary's Hospital, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University, Seoul
Hospital Universitario Vall d Hebron, Barcelona
Institut Catala d Oncologia Hospitalet, Barcelona
Hoffmann-La Roche
INDUSTRY